Somnomed Limited

As of June 30, 2026, Somnomed Ltd. carries a market capitalization of 94.89M, placing it among publicly traded companies globally. Its enterprise value stands at 86.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Somnomed Ltd.'s next confirmed earnings release is scheduled for February 26, 2027.

As of June 30, 2026, Somnomed Ltd. has 217.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.16, and the price-to-book ratio stands at 2.89.

As of June 30, 2026, Somnomed Ltd. trades at an EV/EBITDA multiple of 19.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 128.47 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 86.77M versus a market cap of 94.89M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Somnomed Ltd. maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.51, indicating elevated leverage, while an interest coverage ratio of 107.68 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Somnomed Ltd. posted a negative return on equity (ROE) of -5.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.51, reflecting losses generated across the asset base. Inventory turnover of 4.47 indicates how many times Somnomed Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Somnomed Ltd. recorded 1.52M in income tax expense. The company reported a pretax loss of -316,955.02 and -1.83M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 11, 2026, Somnomed Ltd.'s stock has declined approximately 45.21% over the past 52 weeks. The 50-day moving average sits at 0.47, while the 200-day moving average is 1.02.

Over the twelve months ended June 30, 2026, Somnomed Ltd. generated 79.26M in revenue and converted that into -1.83M in net income, yielding earnings per share of -0.01. EBITDA reached 4.47M, while operating income came in at 675,432.53.

As of June 30, 2026, Somnomed Ltd. holds 11.89M in cash and equivalents against 3.78M in total debt, resulting in a net debt position of -11.60M. Total book value stands at 32.80M, with working capital of 10.85M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Somnomed Ltd. posted a gross margin of 61.13, reflecting its pricing power and cost economics. The operating margin of 0.85 and net profit margin of -2.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 1.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Somnomed Ltd. shareholders.

Somnomed Ltd.'s most recent stock split took place on April 10, 2024.

As of June 30, 2026, Somnomed Ltd. has an Altman Z-Score of 3.43, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.